Global Information
회사소개 | 문의

세계의 망막질환용 의약품 및 생물학적 제제 시장 분석과 예측(2016-2022년)

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022

리서치사 Market Scope, LLC
발행일 2018년 05월 상품 코드 644806
페이지 정보 영문
가격
US $ 6,800 ₩ 7,675,800 Hard Copy
US $ 7,300 ₩ 8,240,200 Hard Copy & PDF by E-mail (Single User License)
US $ 10,200 ₩ 11,513,700 Hard Copy and PDF by E-mail (Enterprise License)


세계의 망막질환용 의약품 및 생물학적 제제 시장 분석과 예측(2016-2022년) 2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022
발행일: 2018년 05월 페이지 정보 : 영문

한글목차

각종 망막질환 의약품 및 생물학적 제제(Retinal Pharmaceuticals and Biologics) 시장을 조사했으며, 주요 망막질환 개요, 위험인자, 진단과 관리, 치료법, 주요 출시 의약품 개요, 개발중인 제품 개요, 시장 성장 영향요인, 각종 구분별 시장 규모 추이와 예측, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

1. 서론

2. 주요 요약

3. 망막

4. 서론 : 망막질환

  • 치료 형태
  • 치료 표적
  • 세계의 망막질환 예측

5. 노인성 황반변성(AMD)

  • 건성 AMD
  • 지도모양 위축(GA)
  • 습식(신생혈관형) AMD
  • 폴립상 맥락막 혈관병증(PCV)
  • 망막혈관종증
  • AMD 위험인자
  • 증상
  • 진단과 관리
  • 진단 기술
  • 치료법
  • 약물 치료
  • 생물학적 요법
  • 레이저 치료
  • 노인성 황반변성 추정
  • 노인성 황반변성 : 카테고리별

6. 당뇨병성 안질환

  • 당뇨병
  • 당뇨병성 망막증
  • 비증식성 당뇨병성 망막증
  • 증식성 당뇨병성 망막증(PDR)
  • 당뇨병성 황반부종(DME)
  • DR/DME 위험인자
  • 혈당 수치, 혈압, 혈중 지방질
  • 인종과 민족
  • Glitazones, DME
  • 진단 및 관리
  • 약물 치료
  • 생물학적 제제
  • 레이저 치료
  • 동결요법
  • 초자체 절제술
  • 당뇨병성 안질환(DR, DME) 추정
  • 당뇨병성 안질환 : 카테고리별

7. 망막 정맥 폐쇄

  • 망막 중심 정맥 폐쇄
  • 망막 정맥 분지 폐쇄
  • 위험인자
  • 질환과 증상
  • 성별
  • 생활습관 요인
  • 진단 및 관리
  • 약물 치료
  • 생물학적 제제
  • 레이저 치료
  • 망막 정맥 폐쇄 추정
  • 망막 정맥 폐쇄 : 카테고리별

8. 유착, 원공, 열공, 박리

  • 증상성 유리체황반 부착(VMA)
  • 망막 열공, 원공, 박리
  • 망막 박리
  • 망막 원공, 열공, 박리 추정

9. 유전성 망막증

  • 색맹
  • 범맥락막위축(Choroideremia)
  • 레버 선천성 흑암시(Leber Congenital Amaurosis)
  • 스타가르트 황반변성(Stargardt Macular Degeneration)
  • 어셔 증후군(Usher Syndrome)
  • 기타
  • 유전성 망막증 추정

10. 비감염성 후포도막염

  • 추정
  • 치료

11. 근시성 맥락막 신생혈관 생성

  • 추정
  • 치료

12. 기타 망막질환

13. 환자 경제와 상환

  • 치료, 접근, 비용
  • 비용 제어
  • 경쟁

14. 망막 전문의

15. 출시된 의약품

  • 항VEGF 이전의 치료
  • 생물학적 제제
  • 역사
  • 바이오시밀러의 정의
  • Lucentis : Genentech(Roche), Novartis
  • Avastin : Genentech(Roche)
  • Lucentis, Avastin 비교
  • Lucentis, Avastin 매출
  • Macugen : Valeant Pharmaceuticals/Pfizer
  • Eylea : Regeneron/Bayer Healthcare
  • Conbercept : Chengdu Kanghong Biotech
  • 항VEGF 요법
  • ThromboGenics : Jetrea
  • AbbVie : Humira
  • Acthar : Mallinckrodt
  • Visudyne(광선역학요법) : Valeant
  • 의약품/Novartis
  • 안과용 부신피질 스테로이드제(ICS)
  • Raxone : Santhera Pharmaceuticals 등

16. 개발중인 의약품

  • VEGF 저해제
  • Novartis : Brolucizumab(RTH258)
  • Allergan : Abicipar pegol(AGN-150998)
  • Ohr Pharmaceuticals : Squalamine(OHR-102), Lucentis 등

17. 임상시험 중인 서방성 전달 기기

  • Allergan
  • Roche

18. 세계 시장 예측

  • 시장 개요와 성장 촉진요인
  • 매출 촉진요인과 성장 억제요인
  • 주요 예측 컴포넌트
  • 망막 치료제 및 생물학적 제제 시장
  • 시장 개요 : 지역별
  • 지도상 위축(GA) 치료제
  • 유전성 망막증 치료제

19. 뉴트라슈티컬

20. 미국 노화 관련 눈질환연구회(AREDS)의 조사결과

21. 새로운 비약리요법

  • 레이저 치료
  • Ellex : 망막 재생요법(2RT)
  • 표적 레이저 광응고술
  • 방사선 요법
  • 의료기기 등

22. 기업 개요

LSH 18.06.11

영문목차

Our report on the retinal pharmaceuticals and biologics market is in its eighth edition. It is a leading industry source for accurate and relevant information on all aspects of the market. We cover prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We discuss the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and analyze treatment patterns and trends. We also forecast product demand in units and dollars, and we analyze market shares by product category.

What's New? The 2017 Retinal Pharmaceuticals and Biologics Report has significant enhancements from previous reports, with updated estimates of the prevalence of diabetes and new extended analysis and discussions of diseases.

We analyze worldwide markets using the following geographic/economic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America and Rest of World. This report includes market data for 2016, and we forecast market performance through 2022.

Market Scope's 2017 Retinal Pharmaceuticals and Biologics Report provides in-depth coverage of current and future pharmaceuticals and biologics used in treating retinal diseases.

ABOUT THE AUTHOR

image2

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry.


Eight Categories Are Analyzed In This Report:

VEGF Inhibitors, PDGF Inhibitors, Neuroprotectors, Complement Cascade Inhibitors, Visual Cycle Modulators, Gene Therapies, Corticosteroids, and Other Mechanisms of Action

Each Market Segment Includes:

An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

Also Included in This Report:

  • Review of Retinal Diseases and Treatments
  • Symptoms, Diagnosis, and Treatment of AMD
  • Diagnosis and Management of Diabetic Retinopathy and Macular Edema
  • An Overview of Other Retinal Diseases and Conditions
  • Epidemiology of Retinal Disease
  • Patient Economics and Reimbursement
  • Retina Specialists and Training
  • Current Retinal Pharmaceuticals in the Marketplace
  • 27 Company Profiles
  • 41 Color Tables and 47 Color Figures

image1

Table of Contents

INTRODUCTION

  • Scope
  • Methodology
  • About the Author
  • The Report at a Glance

EXECUTIVE SUMMARY

  • Transformative Years
  • Market Drivers
  • The Retinal Pharmaceutical Products Market
  • Leading Competitors' Revenues
  • Leading Competitors' Units
  • Market Trends

THE RETINA

INTRODUCTION TO RETINAL DISEASES

  • Treatment Modalities
  • Therapeutic Targets
  • Global Retinal Disease Forecast

AGE-RELATED MACULAR DEGENERATION

  • Dry AMD
  • Geographic Atrophy (GA)
  • Wet (Neovascular) AMD
  • Polypoidal Choroidal Vasculopathy (PCV)
  • Retinal Angiomatous Proliferation
  • Simultaneous Neovascular AMD and GA
  • AMD Risk Factors
  • Symptoms of AMD
  • Diagnosis and Management
  • Diagnostic Technologies
  • Therapies
  • Pharmaceutical Therapy
  • Biologic Therapy
  • Laser Therapy
  • Estimates for Age-Related Macular Degeneration
  • Age-Related Macular Degeneration by Category

DIABETIC EYE DISEASE

  • Diabetes
  • Diabetic Retinopathy
  • Nonproliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy (PDR)
  • Diabetic Macular Edema (DME)
  • DR and DME Risk Factors
  • Blood Glucose, Blood Pressure and Blood Lipids
  • Race and Ethnicity
  • Glitazones and DME
  • Diagnosis and Management
  • Pharmaceutical Therapy
  • Biologics Therapy
  • Laser Therapy
  • Cryotherapy
  • Vitrectomy
  • Estimates for Diabetic Eye Diseases (DR and DME)
  • Diabetic Eye Disease by Category

RETINAL VEIN OCCLUSION

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion
  • Risk Factors
  • Diseases and Conditions
  • Gender
  • Lifestyle Factors
  • Diagnosis and Management
  • Pharmaceutical Therapy
  • Biologics Therapy
  • Laser Therapy
  • Estimates for Retinal Vein Occlusion
  • Retinal Vein Occlusion by Category

ADHESIONS, HOLES, TEARS, AND DETACHMENTS

  • Symptomatic Vitreomacular Adhesion (VMA)
  • Retinal Tears, Holes, and Detachments
  • Retinal Detachment
  • Estimates for Retinal Holes, Tears, and Detachments

INHERITED RETINOPATHIES

  • Achromatopsia
  • Other Heritable Color Vision Defi ciency
  • Choroideremia
  • Leber Congenital Amaurosis
  • Leber Hereditary Optic Neuropathy
  • Stargardt Macular Degeneration
  • Usher Syndrome
  • X-linked Juvenile Retinoschisis
  • Retinitis Pigmentosa
  • Additional Inherited Retinal Dystrophies
  • Estimates for Inherited Retinopathies

NONINFECTIOUS POSTERIOR UVEITIS

  • Estimates for Noninfectious Posterior Uveitis
  • Treatment

MYOPIC CHOROIDAL NEOVASCULARIZATION

  • Estimates for Myopic Choroidal Neovascularization
  • Treatment

ADDITIONAL RETINAL DISEASES

  • Central Serous Chorioretinopathy (CSCR)
  • CMV Retinitis
  • Epiretinal Membrane (ERM)
  • Infectious Chorioretinitis
  • Retinal Artery Occlusion
  • Retinoblastoma
  • Retinopathy of Prematurity (ROP)
  • Estimates for Other Retinal Diseases

PATIENT ECONOMICS AND REIMBURSEMENT

  • Treatment, Access, and Cost
  • Cost Controls
  • Competition

RETINA SPECIALISTS

  • Retinal Training
  • The Retina Subspecialty Worldwide
  • Vitreoretinal Services
  • Diagnosing and Monitoring
  • Treatment
  • Location of Retinal Services
  • Conferences and Associations
  • Retina Meetings
  • Retina Societies

RETINAL PHARMACEUTICALS IN THE MARKET

  • Treatment before Anti-VEGFs
  • Biologics
  • History
  • Biosimilars Defi ned
  • Lucentis from Genentech (Roche) and Novartis
  • Avastin from Genentech (Roche)
  • Comparisons of Lucentis and Avastin
  • Sales of Lucentis and Avastin
  • Macugen from Valeant Pharmaceuticals/Pfi zer
  • Eylea from Regeneron/Bayer Healthcare
  • Conbercept from Chengdu Kanghong Biotech
  • Anti-VEGF Regimens
  • ThromboGenics' Jetrea
  • AbbVie's Humira
  • Acthar from Mallinckrodt
  • On the Horizon
  • Pharmaceuticals
  • Visudyne (Photodynamic Therapy) from Valeant
  • Pharmaceuticals/Novartis
  • Ophthalmic Corticosteroids
  • Raxone from Santhera Pharmaceuticals
  • On the Horizon
  • Summary Table of Treatments for Retinal Disease
  • Other Marketed Pharmaceuticals with Retinal
  • Applications

RETINAL PHARMACEUTICALS IN DEVELOPMENT

  • VEGF Inhibition
  • Novartis: Brolucizumab (RTH258)
  • Allergan: Abicipar pegol (AGN-150998)
  • Ohr Pharmaceuticals: Squalamine (OHR-102) used in
  • conjunction with Lucentis
  • Other New Anti-VEGFs in Development
  • PDGF and VEGF Inhibition
  • Other Vascular Growth Factor Inhibitors
  • Kinase Inhibition
  • RNA Interference
  • Ang-2 Inhibition
  • Tie2 Activation
  • Endoglin Inhibition
  • Tissue Factor Inhibition
  • Targeting the Complement Cascade
  • Genentech (Roche): Lampalizumab (Anti-Factor D)
  • Ophthotech: Zimura (ARC1905)
  • Other Complement Factor Inhibitors in Development
  • Antisense Technology
  • Gene Signal: Aganirsen
  • Neuroprotection
  • Allergan: Brimonidine IVT Implant
  • Other Neuroprotectors in Development
  • Mitochondrial Protection
  • Modulating the Visual Cycle
  • Novelion Therapeutics: Zuretinol Acetate
  • Other Visual Cycle Modulators
  • Plasma Kallikrein Inhibitors
  • Amyloid Antibodies
  • Gene Therapies
  • Spark Therapeutics: Luxturna (voretigene
  • neparvovec)
  • GenSight: GS010 (rAAV2-ND4)
  • Huazhong University of Science and Technology:
  • rAAV2-ND4
  • Optogenetics
  • Other Gene Therapy Studies
  • Stem Cell Therapies
  • Anti-infl ammatories
  • Corticosteroids
  • Cytokine Signaling Inhibitors
  • Other Mechanisms of Action
  • MacuCLEAR: MC-1101
  • Recap of Programs in Phase III Development

INVESTIGATIONAL SUSTAINED-DELIVERY DEVICES

  • Allergan: Brimonidine IVT Implant
  • Roche: Ranibizumab Port Delivery System

GLOBAL MARKET FORECASTS

  • Market Snapshot and Drivers
  • Factors Depressing Market Revenues
  • Factors Increasing Market Revenues
  • Key Forecast Components
  • Market for Retinal Pharmaceuticals and Biologics
  • The Global Market
  • Global Retinal Disease Market Forecast
  • Treatment Rate
  • New Products Will Increase Diversity of Choices,
  • Return Growth to Total Market Revenues
  • Market Overview by Region
  • The US: A Mature Market Awaits New Products
  • W. Europe: First to Treat Inherited Retinal Disease
  • Japan: Slow Growth
  • Other Wealthy Nations: Uneven Prospects
  • China: Extending Access
  • India: Low-Cost Pioneer
  • Latin America: Going to Extremes
  • Rest of World (ROW): Above Average Growth
  • Notes on Forecasts
  • Therapeutics for Geographic Atrophy
  • Therapeutics for Inherited Retinopathies

NUTRACEUTICALS

AREDS FINDINGS

  • AREDS
  • AREDS2
  • OCULAR DYES
  • Trypan Blue
  • Indocyanine Green
  • Infracyanine Green
  • Brilliant Blue Green
  • Natural Dyes
  • Supplier

NEW NONPHARMACOLOGICAL THERAPIES

  • Laser Therapy
  • Ellex' Retinal Regeneration Therapy (2RT)
  • Targeted Laser Photocoagulation from OD-OS
  • Radiation Therapies
  • IRay Stereotactic Radiotherapy
  • Hand-held Brachytherapy Device from Salutaris
  • Medical Devices
  • Electrical Neurostimulation for Slowing RP's Vision
  • Loss
  • Low-Energy Electrical Stimulation - Okuvision GmbH
  • Implants for Regaining Lost Vision
  • Retinal Prosthesis Projects
  • Implantable Miniature Telescope from VisionCare

COMPANY PROFILES

  • AbbVie Inc.
  • Alcon, Inc.
  • Alimera Sciences
  • Allegro Ophthalmics
  • Allergan, Plc.
  • Apellis Pharmaceuticals
  • Bayer HealthCare AG
  • Chengdu Kanghong Biotechnology Co., Ltd.
  • Clearside Biomedical, Inc.
  • Formycon AG
  • Gene Signal
  • Genentech
  • GenSight Biologics
  • Intas Pharmaceuticals Ltd
  • Mallinckrodt Pharmaceuticals
  • Molecular Partners AG
  • Novartis International AG
  • Ophthotech Corporation
  • Ohr Pharmaceutical
  • PFEnex
  • pSivida Limited
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Santen Pharmaceutical Co., Ltd.
  • Santhera Therapeutics
  • Spark Therapeutics
  • ThromboGenics NV
  • Valeant Pharmaceuticals International
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research